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Children with rheumatic disorders may have a wide variety of clinical features 
ranging from fever or a simple arthritis to complex multisystem autoimmune 
diseases. Information about the prevalence of neurological manifestations 
in children with rheumatologic disorders is limited. This review describes 
the neurologic complications of childhood Rheumatic disease either solely 
or combined with symptoms of other organs involvement, as a primary 
manifestation or as a part of other symptoms, additionally.
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Introduction
Neurologic manifestations of rheumatic disorders occur in two forms of primary 
and secondary (1). In primary central nervous system (CNS) involvement, 
inflammation is limited to the brain and spinal cord. However, secondary CNS 
involvement occurs in a variety of conditions including infections, malignancies, 
systemic vasculitides and other collagen vascular diseases (2). Herein, we have 
reviewed the common rheumatic diseases of childhood and their neurological 
manifestations and complications in the central and peripheral nervous system as 
a primary manifestation or as a part of other symptoms, as well.
Henoch-Schönlein Purpura
Henoch-Schönlein purpura (HSP) is the most common vasculitis of small vessels 
in childhood. Approximately 75% of the cases occur in children aged 2-11 years. 
The median age is 5 years (3). HSP is a multisystem disease that affects the skin, 
joints, gastrointestinal tract and kidneys; however, other organs such as the neural 
system may be affected. The etiology of HSP is not fully clear; nonetheless, the 
genetics, environment and antigenic components are involved in it. An antecedent 
upper-respiratory tract infection has been discovered in most children. Bacterial 
and viral infectious agents, drug ingestions and vaccinations have been associated 
with the development of Henoch-Schönlein purpura (4).
Ostergaard et al. (5) reported the neurological manifestations of 26 children with 
HSP. They did not find any cases with seizures, aphasia, ataxia, paresis or cerebral 
hemorrhage, but behavioral changes were present in eight patients (31%). EEG-
abnormalities like slow wave foci, sharp waves and paroxysms were demonstrated 
in 12 patients (46%) during the acute phase of the disease as well. One year follow-
up of these patients showed that only in four patients the EEG-changes were
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persistent. There was a significant association between 
the presence of headache and EEG abnormalities. 
Although the long-term prognosis of HSP is almost 
individually ascribed to renal disease, some rare 
extra-renal  complications  may  cause  morbidity.  For 
this concern, there are several case reports that show 
cerebral vasculitis in children caused by Henoch-
Schonlein purpura (6-8).
Kawasaki Disease
Kawasaki disease (KD) also known as mucocutaneous 
lymph node syndrome is an acute febrile multisystem 
vasculitis affecting medium sized vessels. It usually 
affects children under five years of age and is associated 
with conjunctival and oral erythema, edema of the palms 
and soles (9). Coronary artery aneurysms occur in 25% 
of untreated cases, which may result in myocardial 
infarction. It is evident that the possibility of atypical 
KD should be considered whenever a child presents 
with prolonged fever and myocarditis in association 
with a very high level of ESR (10). Aseptic meningitis 
is the most common neurologic manifestation of KD; 
however, hemiplegic strokes, acute encephalopathy, 
irritability and facial palsy are also described (11,
12). In children with KD, there is an acute systemic 
inflammatory vasculitis without fibrinoid necrosis. 
There is also a possible role for anti-endothelial cell 
antibodies in the pathogenesis of the disease (13, 14).
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune 
and multi-system disease with a various spectrum of 
clinical and immune abnormalities. Despite advances 
in our understanding, the etiology of SLE remains 
unknown (15, 16). Estimates of the prevalence of 
neuropsychiatric systemic lupus erythematosus 
(NPSLE) have ranged from 22% to 95% in children (17,
18). Central nervous system (CNS) lupus is a severe 
disease with diagnostic challenges. SLE is sometimes 
diagnosed after patients present for treatment of a 
neurologic  event  and  numerous  children  with  SLE 
have neurologic symptoms of the disease (19, 20). 
Neuropsychiatric syndromes associated with SLE are 
aseptic meningitis, stroke, demyelinating syndrome, 
headache,  chorea,  myelopathy,  seizures,  anxiety/
mood disorders, psychosis, Guillain-Barre´ syndrome, 
plexopathy, cranial and/or peripheral neuropathy, 
myasthenia gravis, autonomic disorder and migraine 
(20, 21).
Mild to moderate mental retardation and serious 
emotional and social problems might be the first 
manifestation of children with SLE who are complicated 
with   Klinefelter’s  syndrome   (22).   Drug  induced 
lupus (eg, phenytoin, hydralazine, procainamide and 
isoniazid) is different from classic SLE. Usually, in 
drug induced lupus, antihistone antibody is positive 
and there is neither kidney nor CNS involvement (23). 
Autoantibody against the N-terminal 120 kDa form 
of a-fodrin is a specific and sensitive disease marker 
for both juvenile and adult Sjogren syndrome. Epitope 
mapping  of  this  protein  using  dot  blot  analysis 
have shown that a-fodrin is in association with the 
development of neurological complications or the 
disease progression of both Sjogren and SLE (24).
Behcet’s Disease
Behcet’s disease (BD) is a multisystem disease with an 
unknown etiology, characterized by recurrent oral and 
genitalia ulceration and panuveitis. Recent studies have 
shown that BD is much more frequent than we had 
thought and genetic factors have long been implicated 
in the disease (25). Neurologic involvement in Behçet 
disease was first reported by Knapp in 1941. Pallis 
and Fudge (1956) and Wadia and Williams (1957) 
described the clinical syndromes and classification of 
BD later (26).
Neuro-Behçet’s disease (NBD) is caused by two 
mechanisms; which are as following; 1. primary neural 
parenchymal lesions, 2.secondary to major vascular 
involvement (27). These two types of involvement rarely 
occur in the same individual. Meningoencephalitis, 
spinal cord syndromes, meningitis and encephalopathy, 
optic neuropathy, facial weakness, vestibular 
disturbance, vertigo, sensory neural deafness, cortical 
venous thrombosis, intercranial hypertension, ataxia, 
ocular motor dysfunction, dysarthria, dysphagia, 
isolated cranial nerve lesions (nerve VII was the most), 
severe transverse myelitis with paraplegia, Brown 
Sequard syndrome, hemiparesis and hemisensory 
disturbance, seizure and hippocampal complex partial
Iran J Child Neurology Vol 6 No 4 Autumn 2012 3
Neurologic Manifestations of Childhood Rheumatic Diseases
seizures have been reported (27-31).
Ideguchi  et  al.  studied  412  patients  with  BD, of 
whom 54 (13%) had neuro-Behçet’s disease (NBD). 
According to their report, NBD was significantly 
higher in males (P = 0.009). The majority of patients 
(n = 38, 70%) had acute parenchymal NBD, 15 (28%) 
had chronic progressive parenchymal NBD and one 
(2%) had the non-parenchymal type. Headache and 
fever were more frequently reported by patients with 
acute parenchymal involvement. Personality changes, 
sphincter disturbances, involuntary movements and 
ataxia occurred predominantly in patients with chronic 
progressive parenchymal disease. Lesions were 
distributed throughout the CNS, but mainly in the 
brainstem, white matter and basal ganglia. Analysis of 
end-point clinical outcomes of their patients revealed 
a poor prognosis for patients with chronic progressive 
NBD (32).
Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is the most common 
pediatric rheumatic disease and is associated with 
significant long-term morbidity and mortality. JIA 
is an exclusion diagnosis that applies to any arthritis 
of unknown persisting for more than 6 weeks with 
an onset before the age of 16 years (33, 35). A wide 
spectrum of neurological conditions occur in JIA, 
mostly in systemic onset JIA including neuropathy, 
encephalopathy, vasculitis, seizure and macrophage 
activation syndrome (36-38). Cervical spine disease 
in polyarthritis JIA can cause atlantoaxial subluxation, 
which can lead to cord compression, or more commonly, 
the persistence of a neurological deficit from the spinal 
cord, with sensory and/or motor signs that usually 
deserves surgical intervention (39).
Periodic Fever Syndromes
Neonatal onset multi-inflammatory disease or chronic 
infantile neurologic cutaneous and articular (NOMID/ 
CINCA), familial Mediterranean fever (FMF), periodic 
fever, aphthous stomatitis, pharyngitis, adenitis 
syndrome (PFAPA) and hyper IgD syndrome are the 
most common periodic fever syndromes in childhood. 
NOMID/CINCA  syndrome is an unusual disorder 
that mimics systemic juvenile idiopathic arthritis.
Its onset is during the first year of life. Clinical 
manifestations   include  hectic  fever,  intermittent 
rash,    lymphadenopathy,    hepatosplenomegaly, 
uveitis, cognitive and developmental delay, chronic 
meningitis, hydrocephalus, seizures, papilledema and 
deforming arthropathy with periosteal changes and 
bony overgrowth (40). Almost all patients have chronic 
meningitis from infancy and hydrocephalus, and 
ventriculomegaly can present in utero.
Familial Mediterranean fever is an autosomal recessive 
disorder  characterized  by  recurrent  attacks  of  fever 
and painful inflammatory manifestations in one or two 
sites. It is an ethnically restricted genetic disease found 
commonly among the Mediterranean population, as 
well as Armenians, Turks, Arabs and Jews. The disease 
is caused by mutations in the MEFV gene, encoding the 
Pyrin protein (41). Kalyoncu et al. reported a case series 
of FMF patients with CNS involvement. According to 
their study, of the 8864 patients in the genetic testing 
database, 18 with neurologic signs were assessed. The 
mean age of the patients was 31.0±11.8 years, the mean 
age of the first FMF symptom was 12.6±5.6 years, and 
the mean age of neurologic involvement was 25.8±
12.2 years. Almost 50% of the patients were women. A 
homozygote MEFV mutation was detected in 16 of 18 
patients (88.8%) and a homozygote M694V mutation 
was found in 72.2% of the patients. They found seven 
FMF  patients  with  demyelinating  lesions,  seven 
with cerebrovascular disease and four with posterior 
reversible leukoencephalopathy syndrome (PRES). All 
patients in the PRES group had hypertension. 
Demyelinating lesions and cerebrovascular disease 
were the most common clinical presentations (42).
Anti-Neutrophil Cytoplasmic Antibody (ANCA)
Associated Vasculitis
ANCA    associated   vasculitis   (AAV)   comprises 
three syndromes with systemic vasculitis including 
Wegener’s granulomatosis, Churg Strauss syndrome 
and microscopic polyangiitis, which all involve small 
and medium sized vessels and are associated with 
ANCA (43).
Granulomatosis with polyangitis or Wegener’s 
granulomatosis (WG) is a vasculitis associated 
primarily with pulmonary and renal involvement.
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It is histologically distinguished by the presence of 
necrosis, granulomatous inflammation and vasculitis. 
In a large series of 324 patients with WG, 33.6% had 
neurological involvement. The commonest features 
included peripheral neuropathies, cranial neuropathy, 
ophthalmoplegia, cerebrovascular events and seizures 
(44).
Churg-Strauss syndrome (CSS) or allergic granulomatous 
angiitis, is a rare syndrome that affects small- to 
medium-sized arteries and veins.
The American College of Rheumatology has proposed
6 criteria for the diagnosis of Churg-Strauss syndrome 
and mononeuritis multiplex or polyneuropathy is one of 
these criteria (45). In a study conducted by Sehgal et al., 
of the 47 patients with CSS, 29 (62%) had neurologic 
involvement. Peripheral neuropathy was detected in 25 
patients; of which 17 had multiple mononeuropathy, 
seven had distal symmetric polyneuropathy and one 
had asymmetric polyneuropathy (46). Chorea and 
hemiplegia have also been reported in children with 
CSS (47, 48).
Polyarteritis nodosa (PAN) is a systemic necrotizing 
vasculitis that typically affects medium-sized muscular 
arteries with occasional involvement of small muscular 
arteries. Microscopic polyangiitis (MPA) has been 
accepted as individual disease and the usual availability 
and identification of ANCA testing as important 
to diagnosing vasculitides other than PAN, have 
recognized more patients with vasculitis who don’t 
have simple PAN (49). The neurological conditions 
found include headache, seizure, stroke, mononeuritis 
multiplex and symmetrical polyneuropathy (49, 50).
Primary CNS vasculitis
Primary CNS vasculitis of childhood is a serious, but 
potentially reversible inflammatory brain disease (51). 
A small number of case reports have described fatalities 
resulting from this disease. Although the neurological 
compromise observed at initial presentation may be 
very grave and even life-threatening; however, most 
children survive (52). The Calabrese diagnostic criteria 
for primary angiitis of the CNS in adults were described 
in 1992 (53) that were a newly acquired neurological 
deficit, angiographic and/or histologic evidence of 
CNS vasculitis and absence of a systemic condition
associated with these findings. However, no diagnostic 
criteria for children are available. Therefore, the adult 
definition is applied in practice for children. No peak 
in age distribution has been identified for primary CNS 
vasculitis. A wide spectrum of clinical presentation in 
patients with primary CNS vasculitis of childhood is 
perceived, ranging from an insidious onset of headache, 
behavior changes or psychosis, cognitive decline, 
seizures, status epilepticus, cranial nerve palsy, stroke 
and optic neuritis (mostly bilateral) have also been 
reported. The presentation may be affected by the type 
of vascular lesion (large-medium versus small vessel), 
in addition to the location of detached lesions (54-56).
Discussion
We have reviewed the CNS manifestations of common 
rheumatic disorders of childhood including Henoch-
Schonlein purpura, Kawasaki disease, systemic lupus 
erythematosus, Behcet’s disease, juvenile idiopathic 
arthritis, CINCA syndrome, familial Mediterranean 
fever, Wegener’s granulomatosis, Churg strauss 
syndrome, polyarteritis nodosa, and primary CNS 
vasculitis.Thepresenceand thedegreeofnervoussystem 
impairment vary widely, depending on the diagnosis 
and course of the disorder. Severe CNS involvement 
is associated with poor prognosis and high mortality 
rate. High-dose steroid and cyclophosphamide (oral 
or intravenous) are first choice drugs in the treatment; 
plasmapheresis, IVIG, thalidomide and intrathecal 
treatment may be valuable in treatment-resistant and 
serious cases. Manifestations of neurologic disease 
may precede the onset of any other symptoms or may 
occur much later.
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